AR044338A1 - Vacuna aviar de e .coli para la proteccion contra colibacilosis - Google Patents

Vacuna aviar de e .coli para la proteccion contra colibacilosis

Info

Publication number
AR044338A1
AR044338A1 ARP040101654A ARP040101654A AR044338A1 AR 044338 A1 AR044338 A1 AR 044338A1 AR P040101654 A ARP040101654 A AR P040101654A AR P040101654 A ARP040101654 A AR P040101654A AR 044338 A1 AR044338 A1 AR 044338A1
Authority
AR
Argentina
Prior art keywords
coli
vaccine
colibacilosis
protection against
mutant
Prior art date
Application number
ARP040101654A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR044338A1 publication Critical patent/AR044338A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Vacuna atenuada de E. coli mutante con eliminación genética, adecuada para la aplicación masiva a aves de corral, entre ellas, pollos. Método para la protección de aves de corral contra la infección y enfermedades de bacilosis por Escherichia coli, en el cual se administra a pollos, pavos y similares un inmunógeno atenuado mutante de E. coli con eliminación de gen aroA, mediante vías de aplicación masiva tales como pulverizaciones comunes y agua de beber.
ARP040101654A 2003-05-14 2004-05-14 Vacuna aviar de e .coli para la proteccion contra colibacilosis AR044338A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47047103P 2003-05-14 2003-05-14

Publications (1)

Publication Number Publication Date
AR044338A1 true AR044338A1 (es) 2005-09-07

Family

ID=33476714

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101654A AR044338A1 (es) 2003-05-14 2004-05-14 Vacuna aviar de e .coli para la proteccion contra colibacilosis

Country Status (28)

Country Link
US (2) US7357935B2 (es)
EP (1) EP1622642B1 (es)
JP (2) JP5334029B2 (es)
KR (1) KR101106024B1 (es)
CN (1) CN100387299C (es)
AR (1) AR044338A1 (es)
AT (1) ATE380557T1 (es)
AU (1) AU2004240584B2 (es)
BE (1) BE2012C053I2 (es)
BR (1) BRPI0410332B1 (es)
CA (1) CA2524942C (es)
CO (1) CO5640040A2 (es)
CY (1) CY1107188T1 (es)
DE (1) DE602004010643T2 (es)
DK (1) DK1622642T3 (es)
ES (1) ES2297448T3 (es)
FR (1) FR12C0073I2 (es)
HK (1) HK1083597A1 (es)
HR (1) HRP20080069T3 (es)
HU (1) HUS1200029I1 (es)
MX (1) MXPA05012218A (es)
NZ (1) NZ543559A (es)
PL (1) PL1622642T3 (es)
PT (1) PT1622642E (es)
SI (1) SI1622642T1 (es)
TW (1) TW200505475A (es)
WO (1) WO2004103402A1 (es)
ZA (1) ZA200509979B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297338B2 (en) * 2003-05-14 2007-11-20 Wyeth Avian vaccine composition for the protection of poultry against disease and infection caused by E. coli and Salmonella
CN101575586B (zh) * 2009-05-31 2011-01-19 华中农业大学 一种支气管败血波氏杆菌基因缺失疫苗及应用
KR101321501B1 (ko) * 2011-09-21 2013-10-29 주식회사 바이오포아 조류 대장균증 백신 조성물 및 이의 제조방법
BRPI1105176A2 (pt) * 2011-11-22 2013-09-10 Unicamp linhagens de escherichia coli, atenuadas para septicemia em aves, vacinas produzidas com essas linhagensm, metodo de produÇço de vacinas e seus usos
US9814769B2 (en) 2014-09-30 2017-11-14 Qatar University Vaccines against pathogenic Escherichia coli and methods of using the same
CN106465698A (zh) * 2016-09-24 2017-03-01 王德 一种预防雏鸡大肠杆菌病的方法
CN106987549B (zh) * 2017-04-26 2020-08-21 河北科星药业有限公司 培养基及相应的预防禽类大肠杆菌病的广谱菌苗的生产方法
KR20190070457A (ko) 2017-12-13 2019-06-21 주식회사 오투파워 이산화염소를 포함하는 닭 대장균증 예방을 위한 음용수 첨가용 조성물
CN112494641B (zh) * 2020-12-02 2022-07-05 青岛易邦生物工程有限公司 一种禽大肠杆菌活疫苗
CN112442473B (zh) * 2020-12-02 2022-10-25 青岛易邦生物工程有限公司 一种禽大肠杆菌疫苗株
CN112695004A (zh) * 2020-12-28 2021-04-23 南通大学 APEC双基因rpoS和arcA缺失菌株及弱毒疫苗
EP4252770A1 (en) 2022-04-01 2023-10-04 Veterinärmedizinische Universität Wien Composition comprising irradiated e. coli
CN116024151B (zh) * 2022-12-13 2024-01-26 南通大学 一种禽致病性大肠杆菌sRNA s078基因缺失菌株及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0040958B1 (en) 1980-05-26 1984-03-14 Ici Australia Limited Process for the synthesis of gamma-unsaturated carboxylic acid esters
JPH085802B2 (ja) 1986-08-13 1996-01-24 日清製粉株式会社 家禽大腸菌症ワクチン
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
US5641491A (en) 1993-06-15 1997-06-24 The Penn State Research Foundation Escherichia coli strain 364 and use of said strain as a vaccine
JPH07206705A (ja) 1993-11-03 1995-08-08 American Cyanamid Co 生インオボ（ｉｎ ｏｖｏ）ワクチン
EP0973865A2 (en) * 1997-04-11 2000-01-26 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Attenuated, invasive vaccines against fish pathogens
GB9806449D0 (en) 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
US7297338B2 (en) 2003-05-14 2007-11-20 Wyeth Avian vaccine composition for the protection of poultry against disease and infection caused by E. coli and Salmonella

Also Published As

Publication number Publication date
CA2524942C (en) 2012-10-23
BE2012C053I2 (es) 2023-08-09
EP1622642A1 (en) 2006-02-08
FR12C0073I2 (fr) 2013-08-16
US7357935B2 (en) 2008-04-15
PL1622642T3 (pl) 2008-03-31
CN100387299C (zh) 2008-05-14
SI1622642T1 (sl) 2008-04-30
HK1083597A1 (en) 2006-07-07
KR101106024B1 (ko) 2012-01-17
HUS1200029I1 (hu) 2017-02-21
DK1622642T3 (da) 2008-03-25
CA2524942A1 (en) 2004-12-02
AU2004240584A1 (en) 2004-12-02
JP2011234721A (ja) 2011-11-24
BRPI0410332A (pt) 2006-05-30
US20080213317A1 (en) 2008-09-04
MXPA05012218A (es) 2006-02-08
DE602004010643T2 (de) 2008-12-04
ZA200509979B (en) 2008-11-26
CY1107188T1 (el) 2012-10-24
AU2004240584B2 (en) 2010-01-07
DE602004010643D1 (de) 2008-01-24
EP1622642B1 (en) 2007-12-12
CO5640040A2 (es) 2006-05-31
FR12C0073I1 (es) 2013-01-18
ES2297448T3 (es) 2008-05-01
JP2007500745A (ja) 2007-01-18
NZ543559A (en) 2008-02-29
US20040234534A1 (en) 2004-11-25
US7575754B2 (en) 2009-08-18
CN1822855A (zh) 2006-08-23
ATE380557T1 (de) 2007-12-15
KR20060012612A (ko) 2006-02-08
BRPI0410332B1 (pt) 2019-10-08
PT1622642E (pt) 2008-02-18
WO2004103402A1 (en) 2004-12-02
HRP20080069T3 (en) 2008-03-31
JP5334029B2 (ja) 2013-11-06
TW200505475A (en) 2005-02-16

Similar Documents

Publication Publication Date Title
AR044338A1 (es) Vacuna aviar de e .coli para la proteccion contra colibacilosis
UY28757A1 (es) Compuestos de pirazolina substituidos, su preparación y su uso como medicamentos
ECSP088225A (es) 1h-imidazopiridinas sustituidas con hidroxi y procedimientos
CL2008002966A1 (es) Compuesto tetrapeptido ceto-epoxido cristalino; sal citrato cristalina del compuesto; metodos de preparacion; compuesto intermediario cristalino; metodo de preparacion; y uso para tratar cancer, enfermedad autoinmune, afeccion relacionada con trasplante, enfermedad neurodegenerativa, afeccion asociada con fibrosis, entre otros.
NZ607996A (en) Substituted nucleotide analogs
HN1999000183A (es) Preparado farmaceuticos de moxifloxacina
CO5611162A2 (es) Metodos para prevenir enfermedades reproductivas en el ganado vacuno
CL2008002910A1 (es) Composicion base para un desodorante tipo barra que comprende entre 20 y 70% en peso de propilenglicol, 5 a 60% de glicerina, 10 a 35% de agua y un agente espesante; metodo para inhibir el crecimiento bacteriano.
AR052855A1 (es) Composiciones para el cuidado bucal que contienen un extrato de eucalyptus
ECSP045353A (es) Derivados de benzoxazinona, su preparación y aplicación como medicamentos
BR0311189A (pt) Composições farmacêuticas contendo polimorfo a de flibanserin
MX2012003827A (es) Toxina rtx citolitica de gallibacterium anatis.
UY28313A1 (es) Nonadepsipeptidos acilados
BR0308567A (pt) derivados de glicosìdeo e glicosìdeo de ortoéster de apomorfina, análogos, e seus usos
ES2192559T3 (es) Vacuna para la proteccion de aves de corral contra la coccidiosis.
ATE503491T1 (de) Verbesserte anthraximpfstoffe und abgabeverfahren
CR10319A (es) Formulaciones precisas derivadas de acido nodulisporico para combatir parasitos
MX2022003218A (es) Vacunas para abejas y metodos de uso.
ES2159306T3 (es) Vacuna contra coccidiosis en pollos.
AR045416A1 (es) Coadyuvante de linfocitos humanos para vacunas
TW200503755A (en) Avian vaccine composition for the protection of poultry against disease and infection caused by e. coli and salmonella
BR9913132A (pt) Nucleotìdeos da antitrombina e proteìnas do moscão
AR041090A1 (es) Uso de toxina labil al calor de esterichia coli como adyuvante en pajaros y aves de corral
RU2009147591A (ru) Способ кормления индюшат
PE20071135A1 (es) Derivados de alquilfosfolipidos con citotoxicidad reducida

Legal Events

Date Code Title Description
FC Refusal